Galectin Therapeutics Inc. (GALT) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
GALT Revenue Growth
GALT Revenue Analysis (2013–2024)
As of May 8, 2026, Galectin Therapeutics Inc. (GALT) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, GALT's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including HALO (+37.6% YoY), AKBA (+25.7% YoY), and MDGL (+256.8% YoY). Compare GALT vs HALO →
GALT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| GALTCurrent | $0 | - | - | - | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% | |
 AKBA | $236M | +25.7% | -4.3% | 9.9% | |
 MDGL | $958M | +256.8% | - | -31.3% | |
 CRNX | $8M | +1978.0% | +155.3% | -6714.8% |
GALT Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $-37,000 | - | $-42,433,000 | - |
| 2023 | $0 | - | $-33,000 | - | $-38,072,000 | - |
| 2022 | $0 | - | $-32,000 | - | $-38,352,000 | - |
| 2021 | $0 | - | $-41,000 | - | $-30,179,000 | - |
| 2020 | $0 | - | $-36,000 | - | $-23,444,000 | - |
| 2019 | $0 | - | $-35,000 | - | $-13,438,000 | - |
| 2018 | $0 | - | $0 | - | $-13,602,000 | - |
| 2017 | $0 | - | $-1,000 | - | $-16,247,000 | - |
| 2016 | $0 | - | $-7,000 | - | $-21,481,000 | - |
| 2015 | $0 | - | $-7,000 | - | $-20,079,000 | - |
See GALT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GALT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GALT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGALT — Frequently Asked Questions
Quick answers to the most common questions about buying GALT stock.
Is GALT's revenue growth accelerating or slowing?
GALT TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is GALT's long-term revenue growth rate?
Galectin Therapeutics Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is GALT's revenue distributed by segment?
GALT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.